Login to Your Account



China’s Push to Stop Corruption

Glaxosmithkline Likely to Skirt Charges in China, but Not the Executives

By Shannon Ellis
Staff Writer

Wednesday, November 6, 2013

SHANGHAI – Authorities are reportedly set on charging London-based Glaxosmithkline plc’s (GSK) Chinese executives on charges of bribery and corruption following initial claims by the Chinese police in July. This would leave the beleaguered GSK free from corporate criminal prosecution, but still facing potential administrative fines, investigations from anti bribery authorities in the U.S. and the UK and a sharp decline in revenues in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription